International nonproprietary name

Last updated

Mandate

The World Health Organization has a constitutional mandate to "develop, establish and promote international standards with respect to biological, pharmaceutical and similar products".

Contents

The World Health Organization collaborates closely with INN experts and national nomenclature committees to select a single name of worldwide acceptability for each active substance that is to be marketed as a pharmaceutical. To avoid confusion, which could jeopardize the safety of patients, trade-marks should neither be derived from INNs nor contain common stems used in INNs.

WHO [1]

An international nonproprietary name (INN) is an official generic and nonproprietary name given to a pharmaceutical drug or an active ingredient. [2] INNs are intended to make communication more precise by providing a unique standard name for each active ingredient, to avoid prescribing errors. [1] The INN system has been coordinated by the World Health Organization (WHO) since 1953. [3]

Having unambiguous standard names for each drug (standardization of drug nomenclature) is important because a drug may be sold by many different brand names, or a branded medication may contain more than one drug. For example, the branded medications Celexa, Celapram and Citrol all contain the same active ingredient: citalopram; and the antibiotic widely known by the brand name Bactrim contains two active ingredients: trimethoprim and sulfamethoxazole. This combination of two antibiotic agents in one tablet has been available as a generic for decades, but the brand names Bactrim and Septra are still in common use.

Each drug's INN is unique but may contain a word stem that is shared with other drugs of the same class; for example, the beta blocker drugs propranolol and atenolol share the -olol suffix, and the benzodiazepine drugs lorazepam and diazepam share the -azepam suffix.

The WHO issues INNs in English, Latin, French, Russian, Spanish, Arabic, and Chinese, and a drug's INNs are often cognate across most or all of the languages, with minor spelling or pronunciation differences, for example: paracetamol (en) paracetamolum (la), paracétamol (fr) and парацетамол (ru). An established INN is known as a recommended INN (rINN), while a name that is still being considered is called a proposed INN (pINN). [3]

Name stems

Drugs from the same therapeutic or chemical class are usually given names with the same stem . Stems are mostly placed word-finally, but in some cases word-initial stems are used. They are collected in a publication informally known as the Stem Book. [4]

Examples are: [4]

Linguistic discussion

Stems and roots

The term stem is not used consistently in linguistics. It has been defined as a form to which affixes (of any type) can be attached. [5] Under a different and apparently more common view, this is the definition of a root, [6] while a stem consists of the root plus optional derivational affixes, meaning that it is the part of a word to which inflectional affixes are added. [7] INN stems employ the first definition, while under the more common alternative they would be described as roots.

Translingual communication

Pharmacology and pharmacotherapy (like health care generally) are universally relevant around the world, making translingual communication about them an important goal. An interlingual perspective is thus useful in drug nomenclature. The WHO issues INNs in English, Latin, French, Russian, Spanish, Arabic, and Chinese. A drug's INNs are often cognates across most or all of the languages, but they also allow small inflectional, diacritic, and transliterational differences that are usually transparent and trivial for nonspeakers (as is true of most international scientific vocabulary). For example, although paracetamolum (la) has an inflectional difference from paracetamol (en), and although paracétamol (fr) has a diacritic difference, the differences are trivial; users can easily recognize the "same word" (although Americans will likely not recognize the word paracetamol in the first place, because that medicine is known as "acetaminophen" in the United States, even among most healthcare professionals, illustrating that the INN system is not perfect in its functioning). [8] And although парацетамол (ru) and paracetamol (en) have a transliterational difference, they sound similar, and for Russian speakers who can recognize Latin script or English speakers who can recognize Cyrillic script, they look similar; users can recognize the "same word". Thus, INNs make medicines bought anywhere in the world as easily identifiable as possible to people who do not speak that language. Notably, the "same word" principle allows health professionals and patients who do not speak the same language to communicate to some degree and to avoid potentially life-threatening confusions from drug interactions.

Spelling regularization

A number of spelling changes are made to British Approved Names and other older nonproprietary names with an eye toward interlingual standardization of pronunciation across major languages. [9] Thus a predictable spelling system, approximating phonemic orthography, is used, as follows:

  • ae or oe is replaced by e (e.g. estradiol vs. oestradiol)
  • ph is replaced by f (e.g. amfetamine vs. amphetamine)
  • th is replaced by t (e.g. metamfetamine vs. methamphetamine)
  • y is replaced by i (e.g. aciclovir vs. acyclovir)
  • h and k are avoided where possible

Names for radicals and groups (salts, esters, and so on)

Many drugs are supplied as salts, with a cation and an anion. The way the INN system handles these is explained by the WHO at its "Guidance on INN" webpage. [2] For example, amfetamine and oxacillin are INNs, whereas various salts of these compounds – e.g., amfetamine sulfate and oxacillin sodium – are modified INNs (INNM). [2] [10]

Comparison of naming standards

Several countries had created their own nonproprietary naming system before the INN was created, and in many cases, the names created under the old systems continue to be used in those countries. As one example, in English the INN name for a common painkiller is paracetamol ; the table below gives the alternative names for this in different systems:

International nonproprietary name (INN)
  • paracetamol (en)
  • paracetamolum (la)
  • paracétamol (fr)
  • paracetamol (es)
  • парацетамол (ru)
  • باراسيتامول (ar)
  • 对乙酰氨基酚 (zh)
Australian Approved Name (AAN)paracetamol [11]
British Approved Name (BAN)paracetamol [12]
acetaminophen [12]
アセトアミノフェン (jp)
acetaminophen (en)
Other generic names
  • N-acetyl-p-aminophenol
  • APAP
  • p-acetamidophenol
  • acetamol
  • etc.
Proprietary names
  • Tylenol
  • Panadol
  • Panodil
  • Panamax
  • Perdolan
  • Calpol
  • Doliprane
  • Tachipirina
  • Ben-u-ron
  • Atasol
  • Adol
  • Pamol
  • Gelocatil
  • etc.
IUPAC name N-(4-hydroxy phenyl)acetamide
ATC codeN02BE01

See also

Related Research Articles

A British Approved Name (BAN) is the official, non-proprietary, or generic name given to a pharmaceutical substance, as defined in the British Pharmacopoeia (BP). The BAN is also the official name used in some countries around the world, because starting in 1953, proposed new names were evaluated by a panel of experts from WHO in conjunction with the BP commission to ensure naming consistency worldwide (an effort leading to the International Nonproprietary Name system). There is also a British Approved Name (Modified) (BANM).

A United States Adopted Name (USAN) is a unique nonproprietary name assigned to a medication marketed in the United States. Each name is assigned by the USAN Council, which is co-sponsored by the American Medical Association (AMA), the United States Pharmacopeial Convention (USP), and the American Pharmacists Association (APhA).

The nomenclature of monoclonal antibodies is a naming scheme for assigning generic, or nonproprietary, names to monoclonal antibodies. An antibody is a protein that is produced in B cells and used by the immune system of humans and other vertebrate animals to identify a specific foreign object like a bacterium or a virus. Monoclonal antibodies are those that were produced in identical cells, often artificially, and so share the same target object. They have a wide range of applications including medical uses.

<span class="mw-page-title-main">Nelivaptan</span> Chemical compound

Nelivaptan (INN) is a selective, orally active, non-peptide vasopressin receptor antagonist selective for the V1B subtype. The drug had entered clinical trials for treatment of anxiety and depression. In July 2008, Sanofi-Aventis announced that further development of this drug had been halted.

A matrix metalloproteinase inhibitor inhibits matrix metalloproteinases. As they inhibit cell migration they have antiangiogenic effects. They may be both endogenous and exogenous.

<span class="mw-page-title-main">Vedaclidine</span> Chemical compound

Vedaclidine (INN, codenamed LY-297,802, NNC 11-1053) is an experimental analgesic drug which acts as a mixed agonist–antagonist at muscarinic acetylcholine receptors, being a potent and selective agonist for the M1 and M4 subtypes, yet an antagonist at the M2, M3 and M5 subtypes. It is orally active and an effective analgesic over 3× the potency of morphine, with side effects such as salivation and tremor only occurring at many times the effective analgesic dose. Human trials showed little potential for development of dependence or abuse, and research is continuing into possible clinical application in the treatment of neuropathic pain and cancer pain relief.

<span class="mw-page-title-main">Vestipitant</span> Chemical compound

Vestipitant (INN) is a drug developed by GlaxoSmithKline which acts as a selective antagonist for the NK1 receptor. It is under development as a potential antiemetic and anxiolytic drug, and as a treatment for tinnitus and insomnia.

<span class="mw-page-title-main">Acefylline</span> Chemical compound

Acefylline (INN), also known as 7-theophyllineacetic acid, is a stimulant drug of the xanthine chemical class. It acts as an adenosine receptor antagonist. It is combined with diphenhydramine in the pharmaceutical preparation etanautine to help offset diphenhydramine induced drowsiness.

<span class="mw-page-title-main">Ezlopitant</span> Chemical compound

Ezlopitant (INN, code name CJ-11,974) is an NK1 receptor antagonist. It has antiemetic and antinociceptive effects. Pfizer was developing ezlopitant for the treatment of irritable bowel syndrome but it appears to have been discontinued.

Lavoltidine (INN, USAN, BAN; previously known as loxtidine, code name AH-23,844) is a highly potent and selective H2 receptor antagonist which was under development by Glaxo Wellcome (now GlaxoSmithKline) as a treatment for gastroesophageal reflux disease but was discontinued due to the discovery that it produced gastric carcinoid tumors in rodents.

<span class="mw-page-title-main">Elinogrel</span> Chemical compound

Elinogrel (INN, USAN) was an experimental antiplatelet drug acting as a P2Y12 inhibitor. Similarly to ticagrelor and in contrast to clopidogrel, elinogrel was a reversible inhibitor that acted fast and short (for about 12 hours), and it was not a prodrug but pharmacologically active itself. The substance was used in form of its potassium salt, intravenously for acute treatment and orally for long-term treatment. Development was terminated in 2012.

<span class="mw-page-title-main">Cenicriviroc</span> Chemical compound

Cenicriviroc is an experimental drug candidate for the treatment of HIV infection and in combination with Tropifexor for non-alcoholic steatohepatitis. It is being developed by Takeda and Tobira Therapeutics.

<span class="mw-page-title-main">Lufuradom</span> Chemical compound

Lufuradom (INN) is a drug and benzodiazepine derivative which, unlike other benzodiazepines, is described as an analgesic. Similarly to its analogue tifluadom, it was never marketed.

Drug nomenclature is the systematic naming of drugs, especially pharmaceutical drugs. In the majority of circumstances, drugs have 3 types of names: chemical names, the most important of which is the IUPAC name; generic or nonproprietary names, the most important of which are international nonproprietary names (INNs); and trade names, which are brand names. Under the INN system, generic names for drugs are constructed out of affixes and stems that classify the drugs into useful categories while keeping related names distinguishable. A marketed drug might also have a company code or compound code.

<span class="mw-page-title-main">Serlopitant</span> Chemical compound

Serlopitant (INN, codenamed VPD-737) is a drug which acts as an NK1 receptor antagonist. It was assessed in clinical trials for the treatment of urinary incontinence and overactive bladder, but while it was superior to placebo it provided no advantage over existing approved drugs, and was not approved for further development for this indication. Serlopitant is now undergoing clinical trials for the treatment of chronic pruritus (itch)

<span class="mw-page-title-main">Remeglurant</span> Chemical compound

Remeglurant is a drug which acts as a selective antagonist of the mGlu5 receptor. It is under development by Merz Pharmaceuticals for the treatment of drug-induced dyskinesia but no development has been reported since at least 2016.

Sufotidine (INN, USAN, codenamed AH25352) is a long-acting competitive H2 receptor antagonist which was under development as an antiulcerant by Glaxo (now GlaxoSmithKline). It was planned to be a follow-up compound to ranitidine (Zantac). When taken in doses of 600 mg twice daily it induced virtually 24-hour gastric anacidity thus closely resembling the antisecretory effect of the proton pump inhibitor omeprazole. Its development was terminated in 1989 from phase III clinical trials based on the appearance of carcinoid tumors in long-term toxicity testing in rodents.

Vobarilizumab is a humanized bispecific nanobody designed for the treatment of inflammatory autoimmune diseases.

<span class="mw-page-title-main">Rolapitant</span> Pharmaceutical drug

Rolapitant (INN, trade name Varubivə-ROO-bee in the US and Varuby in the European Union) is a drug originally developed by Schering-Plough and licensed for clinical development by Tesaro, which acts as a selective NK1 receptor antagonist (antagonist for the NK1 receptor). It has been approved as a medication for the treatment of chemotherapy-induced nausea and vomiting (CINV) after clinical trials showed it to have similar or improved efficacy and some improvement in safety over existing drugs for this application.

<span class="mw-page-title-main">Lanepitant</span> Chemical compound

Lanepitant (INN, code name LY303870) is a drug developed by Eli Lilly which acts as a selective antagonist for the NK1 receptor, and was one of the first compounds developed that act at this target. It was under development as a potential analgesic drug, but despite promising results in initial animal studies, human clinical trials against migraine, arthritis and diabetic neuropathy all failed to show sufficient efficacy to support further development, with the drug being only marginally more effective than placebo and inferior to older comparison drugs such as naproxen. Failure of analgesic action was thought to be due to poor penetration of the blood–brain barrier in humans, but research has continued into potential applications in the treatment of other disorders with a peripheral site of action, such as corneal neovascularization.

References

  1. 1 2 "International Nonproprietary Names". World Health Organization. Archived from the original on 25 October 2013. Retrieved 21 March 2014.
  2. 1 2 3 World Health Organization, Guidance on INN, archived from the original on August 9, 2014, retrieved October 5, 2020.
  3. 1 2 Serafini M, Cargnin S, Massarotti A, Tron GC, Pirali T, Genazzani AA (April 2021). "What's in a Name? Drug Nomenclature and Medicinal Chemistry Trends using INN Publications". Journal of Medicinal Chemistry . 64 (8): 4410–4429. doi:10.1021/acs.jmedchem.1c00181. PMC   8154580 . PMID   33847110.
  4. 1 2 "The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances" (PDF). World Health Organization. 2018. WHO/EMP/RHT/TSN/2018.1. Retrieved 24 June 2022.
  5. Sampson G, Postal PM (2005). The 'language instinct' debate. Continuum International Publishing Group. p. 124. ISBN   978-0-8264-7385-1 . Retrieved 2009-07-21.
  6. Loos EE, Anderson S, Day Jr DH, Jordan PC, Wingate JD. "What is a root?". Glossary of linguistic terms. SIL International . Retrieved 2010-11-28.
  7. Loos EE, Anderson S, Day Jr DH, Jordan PC, Wingate JD. "What is a stem?". Glossary of linguistic terms. SIL International. Retrieved 2010-11-28.
  8. "Paracetamol - different name in USA?". irishhealth.com. Archived from the original on 4 December 2014. Retrieved 4 December 2014.
  9. "General principles for guidance in devising International Nonproprietary Names for pharmaceutical substances*" (PDF). World Health Organization. United Nations. Retrieved 14 February 2014.
  10. "Guidelines on the Use of International Nonproprietary Names (INNS) for Pharmaceutical Substances". World Health Organization. 1997. Archived from the original on 8 November 2011. Retrieved 1 December 2014. In principle, INNs are selected only for the active part of the molecule which is usually the base, acid or alcohol. In some cases, the active molecules need to be expanded for various reasons, such as formulation purposes, bioavailability or absorption rate. In 1975, the experts designated for the selection of INN decided to adopt a new policy for naming such molecules. In future, names for different salts or esters of the same active substance should differ only with regard to the inactive moiety of the molecule. ... The latter are called modified INNs (INNMs).
  11. "Section 1 – Chemical Substances". TGA Approved Terminology for Medicines (PDF). Therapeutic Goods Administration, Department of Health and Ageing, Australian Government. July 1999. p. 97. Archived from the original (PDF) on 11 February 2014.
  12. 1 2 Macintyre P, Rowbotham D, Walker S (26 September 2008). Clinical Pain Management Second Edition: Acute Pain. CRC Press. p. 85. ISBN   978-0-340-94009-9. Archived from the original on 17 August 2016.

Further reading